{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T04:01:00Z","timestamp":1778385660559,"version":"3.51.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,20]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate the epidemiology and characteristics of systemic sclerosis (SSc) overlap syndrome (SSc-OS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study included patients enrolled in the Siriraj Systemic Sclerosis Cohort registry during November 2013 to September 2019. SSc-OS was defined as SSc patients who also met criteria for rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), Sjogren, and\/or antiphospholipid antibody syndrome. Baseline and 1-year characteristics were compared between SSc and SSc-OS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>185 patients (age 50.3\u2009\u00b1\u200911.4 years, 85.4% female, disease duration 2.7 years, 75.1% diffuse cutaneous subset, 75.6% anti-Scl-70 positivity) were included. The incidence and prevalence rate of SSc-OS was 3.2\/100 patient-years and 17.8%. Regarding SSc-OS, 12.4%, 2.2%, 1.1%, 1.6%, and 0.5% of patients were classified as SSc-RA, SSc-SLE, SSc-PM, SSc-RA-SLE, and SSc-SLE-PM. SSc-OS had a higher prevalence of limited cutaneous subset (lcSSc), usual interstitial pneumonia, finger contractures, ESR &amp;gt;20 mm\/hr., globulin &amp;gt;3.5 g\/dL, rheumatoid factor, anti-citrullinated peptide antibody, and antiphospholipid antibodies. LcSSc subset (OR: 11.3, 95%CI: 2.0-62.6) and globulin &amp;gt;3.5 g\/dL (OR: 6.2, 95%CI: 1.6\u201323.6) were associated with SSc-OS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>SSc-OS is associated with the lcSSc subset. RA is the most common overlap syndrome. LcSSc patients with globulin &amp;gt;3.5 g\/dL are associated with SSc-OS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roab079","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T22:42:24Z","timestamp":1634769744000},"page":"899-907","source":"Crossref","is-referenced-by-count":7,"title":["Epidemiology and clinical characteristics of systemic sclerosis overlap syndrome (SSc-OS), and the factors significantly associated with SSc-OS in Thai patients with systemic sclerosis"],"prefix":"10.1093","volume":"32","author":[{"given":"Apichart","family":"Jantarat","sequence":"first","affiliation":[{"name":"Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University , Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5412-4055","authenticated-orcid":false,"given":"Chayawee","family":"Muangchan","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University , Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"key":"2022082013383309200_R1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.berh.2018.10.005","article-title":"Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis","volume":"32","author":"van der Woude","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2022082013383309200_R2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.berh.2018.09.004","article-title":"Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus","volume":"32","author":"Gergianaki","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2022082013383309200_R3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.berh.2018.08.005","article-title":"Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis","volume":"32","author":"Ingegnoli","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2022082013383309200_R4","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.5152\/eurjrheum.2020.19116","article-title":"Systemic sclerosis: to subset or not to subset, that is the question","volume":"7","author":"Johnson","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"2022082013383309200_R5","doi-asserted-by":"crossref","first-page":"875","DOI":"10.17219\/acem\/64334","article-title":"Systemic sclerosis sine scleroderma","volume":"26","author":"Kucharz","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"2022082013383309200_R6","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.3899\/jrheum.101248","article-title":"Clinical and serological hallmarks of systemic sclerosis overlap syndromes","volume":"38","author":"Pakozdi","year":"2011","journal-title":"J Rheumatol"},{"key":"2022082013383309200_R7","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/ard.2008.091348","article-title":"Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database","volume":"68","author":"Walker","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2022082013383309200_R8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/annrheumdis-2013-204487","article-title":"Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis","volume":"74","author":"Moinzadeh","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022082013383309200_R9","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/rheumatology\/ken179","article-title":"The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement","volume":"47","author":"Hunzelmann","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"2022082013383309200_R10","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/1756-185X.12884","article-title":"Clinical characteristics of scleroderma overlap syndromes: comparisons with pure scleroderma","volume":"19","author":"Foocharoen","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"2022082013383309200_R11","first-page":"14","article-title":"Scleroderma overlap syndrome","volume":"13","author":"Balbir-Gurman","year":"2011","journal-title":"Isr Med Assoc J"},{"key":"2022082013383309200_R12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00296-006-0207-3","article-title":"Coexistence of systemic sclerosis with other autoimmune diseases","volume":"27","author":"Caramaschi","year":"2007","journal-title":"Rheumatol Int"},{"key":"2022082013383309200_R13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2018-214127","article-title":"Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases","volume":"78","author":"Acosta-Herrera","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022082013383309200_R14","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1002\/jmv.23670","article-title":"Selective reactivation of human herpesvirus 6 in patients with autoimmune connective tissue diseases","volume":"85","author":"Broccolo","year":"2013","journal-title":"J Med Virol"},{"key":"2022082013383309200_R15","first-page":"581","article-title":"Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","author":"Preliminary criteria for the classification of systemic sclerosis (scleroderma)","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2022082013383309200_R16","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"Van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022082013383309200_R17","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.3899\/jrheum.140236","article-title":"Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects","volume":"41","author":"Diab","year":"2014","journal-title":"J Rheumatol"},{"key":"2022082013383309200_R18","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1002\/art.24038","article-title":"Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud\u2019s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis","volume":"58","author":"Koenig","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2022082013383309200_R19","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2022082013383309200_R20","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2022082013383309200_R21","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022082013383309200_R22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022082013383309200_R23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2022082013383309200_R24","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.autrev.2013.05.002","article-title":"Systemic sclerosis at the crossroad of polyautoimmunity","volume":"12","author":"Elhai","year":"2013","journal-title":"Autoimmune Rev"},{"key":"2022082013383309200_R25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.semarthrit.2020.10.009","article-title":"Systemic sclerosis overlap and non-overlap syndromes share clinical characteristics but differ in prognosis and treatments","volume":"51","author":"Scherlinger","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2022082013383309200_R26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24167","article-title":"Clinical features of systemic sclerosis-mixed connective tissue disease and systemic sclerosis overlap syndromes","author":"Fairley","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022082013383309200_R27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.5114\/ada.2018.72662","article-title":"Overlap syndromes in systemic sclerosis","volume":"35","author":"Wielosz","year":"2018","journal-title":"Postepy Dermatol Alergol"},{"key":"2022082013383309200_R28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/03009742.2016.1153141","article-title":"Lung and gastrointestinal complications are leading causes of death in SCORE, a multi-ethnic Singapore systemic sclerosis cohort","volume":"45","author":"Santosa","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"2022082013383309200_R29","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3899\/jrheum.170953","article-title":"Epidemiology and survival of systemic sclerosis-systemic lupus erythematosus overlap syndrome","volume":"45","author":"Alharbi","year":"2018","journal-title":"J Rheumatol"},{"key":"2022082013383309200_R30","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3899\/jrheum.151425","article-title":"Patients with systemic sclerosis\/polymyositis overlap have a worse survival rate than patients without it","volume":"43","author":"Bhansing","year":"2016","journal-title":"J Rheumatol"},{"key":"2022082013383309200_R31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0961203307078579","article-title":"Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus","volume":"16","author":"James","year":"2007","journal-title":"Lupus"},{"key":"2022082013383309200_R32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear antibodies in systemic sclerosis: an update","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"2022082013383309200_R33","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"2022082013383309200_R34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jbspin.2017.11.006","article-title":"Anti-citrullinated peptides antibodies in systemic sclerosis: meta-analysis of frequency and meaning","volume":"85","author":"Laustriat","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2022082013383309200_R35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/1756-185X.12919","article-title":"Prevalence and predictors of hand involvement in Thai patients with systemic sclerosis","volume":"21","author":"Wangkaew","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"2022082013383309200_R36","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/rheumatology\/keu165","article-title":"Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics\u2014a large multicentre UK study","volume":"53","author":"Kelly","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2022082013383309200_R37","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/acr.21716","article-title":"Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group","volume":"64","author":"Muangchan","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022082013383309200_R38","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-2057-x","article-title":"Inflammatory stays inflammatory: a subgroup of systemic sclerosis characterized by high morbidity and inflammatory resistance to cyclophosphamide","volume":"21","author":"Mitev","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022082013383309200_R39","first-page":"126","article-title":"The role of inflammatory markers in assessment of disease activity in systemic sclerosis","volume":"36","author":"Ross","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2022082013383309200_R40","first-page":"277","article-title":"This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001","volume":"165","author":"American Thoracic Society; European Respiratory Society. American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias","year":"2002","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roab079\/41928301\/roab079.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/5\/899\/45487180\/roab079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/5\/899\/45487180\/roab079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T13:38:57Z","timestamp":1661002737000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/32\/5\/899\/6378636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,10,1]]},"published-print":{"date-parts":[[2022,8,20]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roab079","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2021,10,1]]}}}